Drug Profile


Alternative Names: Atazanavir sulfate; Atazor; BMS-232632; BMS-232632-05; CGP 73547; Reyataz; TAZ

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Bristol-Myers Squibb; Emcure Pharmaceuticals; Gilead Sciences
  • Class Antiretrovirals; Oligopeptides; Pyridines; Small molecules
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 10 May 2017 Bristol-Myers Squibb completes the phase III PRINCE2 trial for HIV-1 Infections (In children, In infants, Combination therapy) in USA, Argentina, Brazil, Chile, Mexico, South Africa, United Kingdom, Poland, Romania, Spain and Russia (PO) (NCT01335698)
  • 16 Feb 2017 Pharmacokinetic results from a phase II/III trial in HIV-1 infections reported at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
  • 01 Feb 2016 Bristol-Myers Squibb completes an extended-access study for HIV-1 infections (NCT01003990)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top